AVANOS MEDICAL, INC.

Avanos Medical reported mixed financial results for the first quarter of 2026. Net sales increased to $182.2 million, up from $167.5 million in the prior year period. However, net income decreased to $5.1 million, resulting in diluted earnings per share of $0.11, down from $0.14. The company continued its restructuring initiatives and integrated the Nexus Medical acquisition, which contributed $5.8 million in net sales during the quarter.

Avanos Medical, Inc. announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners for an enterprise value of $1.272 billion in an all-cash offer. Concurrently, the company reported its first quarter 2026 financial results, with total net sales increasing by 8.8% to $182.2 million. Despite revenue growth, net income and diluted EPS decreased compared to the prior year, while adjusted EBITDA saw a slight increase.

AVANOS MEDICAL, INC. has entered into an Agreement and Plan of Merger dated April 13, 2026, with A-AV HOLDCO I, INC. and A-AV MERGERSUB, INC. This agreement outlines the terms and conditions for the merger, including the conversion of shares, treatment of equity awards, and various representations, warranties, and covenants from all parties involved. The transaction is subject to customary closing conditions.

AVANOS MEDICAL, INC. has entered into an Agreement and Plan of Merger dated April 13, 2026, with A-AV HOLDCO I, INC. and A-AV MERGERSUB, INC. The comprehensive agreement details the terms and conditions of the merger, including the conversion of shares, treatment of equity awards, and employee stock purchase plans. It also outlines the representations, warranties, and covenants of both the company and the acquiring entities, alongside conditions for the merger's completion and potential termination clauses.